Anti-st2 antibody and pharmaceutical composition

By preparing antibody 3H11, which specifically binds to human ST2, and its humanized antibody, the IL-33/ST2 signaling pathway is blocked, solving the problem of poor efficacy of antibody drugs in treating autoimmune diseases in existing technologies, and achieving better therapeutic effects and lower toxic side effects.

WO2026153423A1 Publication Date: 2026-07-23AKESO BIOPHARMA INC
0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/072825
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-01-16
Filing Date
2026-01-15
Publication Date
2026-07-23

AI Technical Summary

Technical Problem

There is still a need to develop new antibody drugs with high affinity for ST2 for the treatment of autoimmune diseases, which have better therapeutic effects and lower toxic side effects.

Method used

Antibody 3H11, which specifically binds to human ST2, and its humanized antibodies (such as 3H11H4L7 and 3H11H4L8) were prepared. These antibodies can effectively block the binding of human ST2 and IL-33 and inhibit the activation of downstream signaling pathways in the IL-33/ST2 pathway.

Benefits of technology

These antibodies can effectively bind to human ST2 and block the IL-33/ST2 signaling pathway, and are used to prevent and treat various immune-mediated diseases such as chronic obstructive pulmonary disease, asthma, and rheumatoid arthritis, with better therapeutic effects and lower toxic side effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided are an anti-ST2 antibody and a pharmaceutical composition. Specifically provided is an anti-ST2 antibody or an antigen-binding fragment thereof. The anti-ST2 antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3, wherein the amino acid sequence of HCDR1 is as shown in SEQ ID NO: 1, the amino acid sequence of HCDR2 is as shown in SEQ ID NO: 2, and the amino acid sequence of HCDR3 is as shown in SEQ ID NO: 3; and the amino acid sequence of LCDR1 is as shown in SEQ ID NO: 4, the amino acid sequence of LCDR2 is as shown in SEQ ID NO: 5, and the amino acid sequence of LCDR3 is as shown in SEQ ID NO: 6. The antibody can bind to human ST2, block the binding of human IL-33 to ST2, and inhibit the activation of downstream signaling pathways of a human IL-33 / ST2 pathway.
Need to check novelty before this filing date? Find Prior Art